Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-591-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110215.29.2-591-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Falsified medicinal products are a global problem, and should be examined in a global context. The reasons behind the problem include the high price of medicines and a lack of awareness among patients, but to a large extent, they are also of a legal nature. This situation is exploited by criminal groups throughout the world. I would therefore like to acknowledge the joint measures taken by the EU institutions and the almost unanimous position adopted by all the political groups on the drafting of a compromise legislative act on this matter. I wish to quote a statement by the former Secretary-General of Interpol, Ronald Noble, comparing the number of victims of terrorism and counterfeit medicines: over a period of 45 years, terrorists killed 65 000 people, whereas counterfeit medicines claimed 200 000 victims in China alone.
I believe that monitoring, control measures, tightening up standards and establishing a mutual recognition system, all of which are emphasised, are good solutions from which to begin. As Vice-Chair of the Committee on the Environment, Public Health and Food Safety, I would also like to highlight the role played by information campaigns aimed at patients, and also the imposition of obligations on pharmaceutical companies in this area. Patients should have access to high quality, objective information regarding the way in which medicines are prescribed and their properties."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples